Trial Profile
A 6-week open-label, randomized, multicentre, phase IIIb, parallel-group study, which describes the renal effects of the lipid-regulating agents rosuvastatin and simvastatin in the treatment of subjects with Fredrickson type IIa and IIb dyslipidaemia, including heterozygous familial hypercholesterolemia
Status:
Not stated
Phase of Trial:
Phase III
Latest Information Update: 28 Mar 2006
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary) ; Simvastatin (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia
- Focus Pharmacodynamics
- 28 Mar 2006 New trial record.